Skip to main content

Noritate

Generic: metronidazole

Verified·Apr 23, 2026
Manufacturer
Bausch Health
NDC
0187-5202
RxCUI
213120
Route
TOPICAL
ICD-10 indication
L71.9

Affordability Check

How much will you actually pay for Noritate?

In 30 seconds, see every legitimate way to afford Noritate — Medicare copay, manufacturer copay card, Patient Assistance Program, grants, or cash.

Check my options →

About Noritate

What is this medication?

Noritate is a prescription topical cream that contains the active ingredient metronidazole at a concentration of one percent. It is primarily used for the treatment of inflammatory lesions, such as pimples and red bumps, that are associated with a chronic skin condition known as rosacea. While metronidazole is technically an antibiotic, its effectiveness in treating rosacea is largely attributed to its anti-inflammatory properties, which help to soothe the skin and reduce visible blemishes.

This medication is intended for external use only and is typically applied in a thin layer to the affected areas of the face once per day. It works to improve the overall appearance of the skin by decreasing the redness and swelling caused by the condition. Patients should follow the specific application instructions provided by their healthcare professional and continue using the cream as directed to achieve and maintain the best results for their skin.

Copay & patient assistance

  • Patient Copay Amount: Not Publicly Available
  • Maximum Annual Benefit Limit: Not Publicly Available
  • Core Eligibility Restrictions: Medicaid patients whose plans no longer provide coverage for single-source Bausch Health pharmaceuticals; patients must face financial obstacles; limited to prescribed products included in the Bausch Health Patient Assistance Program.
  • RxBIN, PCN, and Group numbers: Not Publicly Available

External links go directly to the manufacturer's portal. RxCopays does not receive compensation for referrals.

Compare pricing elsewhere

RxCopays doesn't sell drugs or take referral fees. Here are the transparent-pricing directories we recommend checking alongside your insurance formulary.

We deep-link because transparency helps patients. None of these partners pay RxCopays.

Prescribing information

From the FDA-approved label for Noritate. Official source: DailyMed (NLM) · Label effective Jun 1, 2020

Indications and usage
INDICATIONS AND USAGE Noritate is indicated for the topical treatment of inflammatory lesions and erythema of rosacea.
Dosage and administration
DOSAGE AND ADMINISTRATION Areas to be treated should be cleansed before application of Noritate . Apply and rub in a thin film of Noritate once daily to entire affected area(s). Patients may use cosmetics after application of Noritate .
Contraindications
CONTRAINDICATIONS Noritate is contraindicated in those patients with a history of hypersensitivity to metronidazole or to any other ingredient in this formulation.
Drug interactions
Drug Interactions: Oral metronidazole has been reported to potentiate the anticoagulant effect of coumarin and warfarin resulting in a prolongation of prothrombin time. Drug interactions should be kept in mind when Noritate is prescribed for patients who are receiving anticoagulant treatment, although they are less likely to occur with topical metronidazole administration because of low absorption. (See CLINICAL PHARMACOLOGY , Pharmacokinetics .)
Adverse reactions
ADVERSE REACTIONS Safety data from 302 patients who used Noritate (n=200) or vehicle control (n=102) once daily in clinical trials and experienced an adverse event considered to be treatment related include: application site reaction ( Noritate 1, vehicle 1), condition aggravated ( Noritate 1, vehicle 0), paresthesia ( Noritate 0, vehicle 1), acne ( Noritate 1, vehicle 0), dry skin ( Noritate 0, vehicle 2). The majority of adverse reactions were mild to moderate in severity. Two patients treated with Noritate once daily discontinued treatment because of adverse events: one for a severe flare of comedonal acne and one for rosacea aggravated. Additional clinical adverse effects reported spontaneously since the drug was marketed are uncommon and include tingling or numbness of extremities, allergic reactions, skin and eye irritation, rash, headache, nausea and dry mouth. To report SUSPECTED ADVERSE REACTIONS, contact Bausch Health US, LLC at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Use in pregnancy
Pregnancy: Teratogenic Effects: There are no adequate and well-controlled studies with the use of Noritate in pregnant women. Metronidazole crosses the placental barrier and enters the fetal circulation rapidly. No fetotoxicity was observed after oral administration of metronidazole to rats or mice at 200 and 20 times, respectively, the expected clinical dose. However, oral metronidazole has shown carcinogenic activity in rodents. Because animal reproduction studies are not always predictive of human response, Noritate should be used during pregnancy only if clearly needed.

Label text is reproduced as-is from the FDA-approved label. We do not paraphrase, summarize, or omit. Content above is for informational purposes only and is not medical advice. Always consult your prescribing clinician or pharmacist before making decisions about your medication.

Conditions we've indexed resources for

Click a condition to see copay cards, grants, and PA rules specific to it. For the full list of FDA-approved indications, see Prescribing information above.

Medicare Part D coverage

How Noritate appears across Medicare Part D plan formularies nationally. Source: CMS monthly Prescription Drug Plan file (2026-04-30).

Covered by plans

12%

636 of 5,509 plans

Most common tier

Tier 5

On 100% of covering formularies

Prior authorization required

0%

of covering formularies

TierFormularies on this tierShare
Tier 5 (specialty)7
100%

Step therapy: 0% of formularies

Quantity limits: 86% of formularies

Coverage breadth: 7 of 65 formularies

How to read this:plans on the same formulary share tier + PA rules. Your specific plan's copay depends on (a) the tier above, (b) your plan's cost-share for that tier, (c) whether you're in the initial coverage phase or past the 2026 $2,000 out-of-pocket cap. For your exact plan, check its Summary of Benefits or log in to your Medicare.gov account. Copay cards don't apply to Medicare (federal law).

Prior authorization & coverage

PayerPAStep therapyCopay tier

Medicare Part D

Related drugs

How this page is sourced

  • Drug identity verified against openFDA NDC Directory.
  • Label text (when shown) originates from NLM DailyMed.
  • Copay and assistance URLs verified periodically; if you hit a broken link, tell us.